Bone Abstracts

Renal osteodystrophy encompasses the bone histologic abnormalities seen in patients with chronic kidney disease (CKD). The bone-specific alkaline phosphatase (BALP) isoform B1x is exclusively found in serum of some CKD patients. The aim of this study was to examine the relationship between serum BALP isoforms and histologic abnormalities of bone in patients with CKD on chronic dialysis (CKD-5D).Anterior iliac crest bone samples from 40 CKD-5D patients we...

Background: Sun exposure may be limited in Arctic populations and Greenland Inuit have adapted to the Arctic environment. The influence of chronic low vitamin D level on PTH to uphold a normal serum calcium remains to be elucidated.Objective: To describe the association between PTH and factors known to influence PTH-, including vitamin D (25OHD) and calcium, in Arctic populations.Methods: Inuit and non-Inuit in the capital city Nuu...

Background, subjects and methods: Vitamin D insufficiency in older people in the UK is common and may cause secondary hyperparathyroidism and bone loss. In a randomised, double blind intervention trial to optimise “Vitamin D status in Older People’ (VDOP) three oral dosages of vitamin D3 (12 kIU, 24 kIU or 48 kIU/month) were given for 12 months to 375 participants aged over 70 years (ANOVA) adjustment for covariables with results below presented in ascendi...

Background: On cessation of bisphosphonate treatment, while bone mineral density decreases slowly, bone resorptive markers such as C-terminal telopeptide (CTX) increase more quickly and may be useful in monitoring ‘offset’ of action. Our aim was to analyse changes in CTX on stopping long-term bisphosphonate treatment to guide clinical decision-making on the duration of treatment cessation (‘drug holidays’).Subjects and methods: A tota...

Urolithiasis is characterized by formation and retention of solid crystals within the urinary tract. There are numerous causes that may lead to urinary stone formation. However, kidney stones are mostly composed of calcium oxalate that predominantly generates free radicals that are toxic to renal tubular cells.The aim of the study is to explore the toxic effect of oxalate to renal epithelial cells and to explore possible effects of antioxidants on its in...

Suppression of parathyroid hormone (PTH) has been suggested as a potential biochemical outcome measure for determining the optimal serum 25-hydroxyvitamin D (S25(OH)D) concentration for bone health in adults. However, in adolescents increases in PTH may not be driven by the same mechanisms and may not be detrimental to bone health. Adolescent studies have provided a wide range of estimates of the S25(OH)D concentration at which PTH plateaus (40–90 nmol/l), with some repor...

Evidence is unclear on the effect of vitamin D intake on vitamin D status in children.Objective: In a meta-analysis, investigate the effect of vitamin D supplements and/or fortified foods on vitamin D status, using the biomarker 25-hydroxyvitamin D (25(OH)D) in children 2–18 years.Methods: Eligible studies were randomized placebo-controlled trials, published in English, in children 2–18 years that compared vitamin D suppl...

Objectives: Childhood osteoporosis can be treated with i.v. bisphosphonates in order to improve bone mass and density. The aims of this study were to evaluate the safety and efficacy of 6-monthly zoledronic acid (ZA) in children with osteoporosis.Methods: A retrospective cohort study of 27 patients (16 males and 11 females) were treated with 6-monthly ZA (0.05 mg/kg per dose) for a minimum of 1 year. Seventeen patients were immobile, 4 had steroid-induce...

Background: Hyperphosphataemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive condition in which increased renal phosphate reabsorption is associated with elevated serum phosphate, inappropriately normal or raised PTH and extraosseous calcification. It is caused by mutations in genes related to phosphate metabolism: fibroblast growth factor 23 (FGF23), UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactos...

Patients with hypoparathyroidism lack sufficient parathyroid hormone (PTH) and exhibit reduced bone turnover, abnormally increased bone mineral density (BMD), and abnormal bone microarchitecture. Current treatment regimens fail to address underlying PTH deficiency. In the REPLACE phase III trial, treatment with rhPTH(1–84) restored mineral homeostasis, increased bone turnover markers (BTMs), and decreased BMD in patients with hypoparathyroidism.REPE...